Krystal Biotech (KRYS) Competitors

Krystal Biotech (NASDAQ:KRYS) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Do analysts rate KRYS or GMAB?

Krystal Biotech currently has a consensus target price of $210.22, suggesting a potential upside of 54.46%. Genmab A/S has a consensus target price of $37.80, suggesting a potential upside of 66.59%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Does the media favor KRYS or GMAB?

In the previous week, Krystal Biotech had 33 more articles in the media than Genmab A/S. MarketBeat recorded 45 mentions for Krystal Biotech and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.72 beat Krystal Biotech's score of 0.46 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	10 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is KRYS or GMAB more profitable?

Krystal Biotech has a net margin of 40.85% compared to Genmab A/S's net margin of 35.11%. Genmab A/S's return on equity of 18.08% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	40.85%	15.21%	13.81%
Genmab A/S	35.11%	18.08%	14.52%

Do insiders and institutionals have more ownership in KRYS or GMAB?

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more risk & volatility, KRYS or GMAB?

Krystal Biotech has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Which has higher earnings and valuation, KRYS or GMAB?

Genmab A/S has higher revenue and earnings than Krystal Biotech. Genmab A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$290.52M	13.56	$89.16M	$4.92	27.66
Genmab A/S	$3.12B	4.66	$1.14B	$1.76	12.89

Summary

Krystal Biotech beats Genmab A/S on 9 of the 16 factors compared between the two stocks.